Therapeutic Solutions International Enters into Multi-Million Dollar Master Sales Agreement with WCTE, Inc.
December 23 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International Enters
into Multi-Million Dollar Master
Sales Agreement
with WCTE, Inc.
Company Started by NFL Chargers Hall of Famer
Wes Chandler Collaborates with TSOI to Provide Nutraceutical
Approach to Chronic Traumatic
Encephalopathy
OCEANSIDE, CA
-- December
23, 2019 --
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI)
announces today the
signing
of another
Master
Sales Agreement with WCTE, Inc.
to
distribute our
nutraceutical line of
products.
"As Therapeutic
Solutions recently announced our Letter of Intent with them to
in-license their adult stem cells to WCTE for Chronic Traumatic
Encephalopathy (CTE) and Traumatic Brain Injury (TBI), we are also
excited today to enter into this Master Sales Agreement with TSOI.
Their products are in a class of their own and even with our own
team of scientists it would take years to develop anything like
them, on our own" said
Wes
Chandler,
Founder, and CEO of WCTE, Inc. "TSOI has literally spent 5 years
developing these products and we are here at the right moment for
the right need at the right time, to take full advantage of the
amazing products coming out of their labs today and the future
products they will develop" added Mr. Chandler.
Products to be
included in this Master Sales Agreement consists of
NanoStilbene,
NeuroStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, and
ProJuvenol.
Future products will be added to the Master List as
commercialized.
"We are so pleased to
close out our year by making this announcement today. As you know
two weeks ago, we entered into a Master Sales Agreement with
Tiva Bio,
also a
Wes
Chandler Founded
Company,
and one
week ago we entered into a Letter of Intent (LOI) with WCTE,
and today
we have provided them
with an
identical agreement as we did
with
Tiva," said Timothy Dixon,
President, and CEO of TSOI.
"At the conclusion of
last year, I spoke of what we thought might happen in 2019 saying
"Looking to 2019 the key things you will see from us will be the
promotion of NanoStilbene and NeuroStilbene and "Right To Try" use
of stem cells and eventually our dendritic cell vaccine for
cancer." The future closing on our Letter of Intent with WCTE will
continue to drive our Right To
Try
program for stem cells in CTE and TBI. We also have a pending
Letter of Intent with Beijing Regenesis Biotechnology Co. Ltd., of
Beijing China to develop and commercialize the anti-aging
properties of cord blood plasma combined with NanoStilbene that we
look to close in early 2020. This year also led to two new
discoveries on pterostilbene worthy of patent application. In one
of these discoveries, we observed that pterostilbene was very
effective at accelerating the recovery of blood cells after
treatment with chemotherapy, a condition called neutropenia. And in
another invention, we teach that pterostilbene augments the ability
of cord blood plasma to suppress biological properties associated
with aging. We are very excited about what 2020 will bring as we
continue to conduct new research, new clinical work, and make new
discoveries." concluded Mr.
Dixon.
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is at
www.therapeuticsolutionsint.com and our
e-commerce is at www.youcanordernow.com and for additional
info on NanoStilbene visit www.mynanostilbene.com.
About
WCTE, Inc.
The
Company was formed because of the urgent unmet need to treat
amateur and professional athletes suffering from Chronic Traumatic
Encephalopathy, who have sacrificed their health and their lives to
for popular entertainment. Now that they need our help, it is
our responsibility to be there for them. The Company has the vision
of identifying, integrating and incorporating the latest
technologies in order to provide a fighting chance for
patients.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
Safe
Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information:
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024